west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "肝肿瘤" 26 results
  • Clinical Efficacy and Status of Image-Guided Ablation of Liver Cancer

    Release date:2016-09-08 11:52 Export PDF Favorites Scan
  • Quality Assessment of the Clinical Studies on Randomized Controlled Trials of Chinese Herb Medicineand Chemotherapy in the Treatment of Hepatocellular Carcinoma

    目的:对中药配合肝动脉栓塞化疗(Transcatheter Arterial Chemoembolization,TACE)辅助治疗原发性肝癌随机对照试验(Randomized controlled trial,RCT)文献进行评价。方法:对国内外公开发表的有关中药配合TACE辅助治疗原发性肝癌的随机对照试验进行检索,检索数据库包括Cochrane图书馆临床对照试验库,MEDLINE、CBM、CNKI和VIP电子数据库。手工检索中文相关期刊以及附加检索相关会议论文集。质量评价采用Jadad评分量表、CONSORT标准和其他自拟评价指标进行分析。结果:共纳入103篇RCTs,其中Jadad评分得5分有1篇文献,3分1篇,2分10篇,71篇1分,其余20篇均为0分,有3篇文献报告了分配隐藏。按CONSORT标准,仅1篇(0.97%)RCT描述了如何产生随机顺序,没有RCT报道如何执行随机,其中1篇为半随机,有1篇(0.97%)RCT采用安慰剂对照,有54篇(52.43%)报道了终点指标,分别各有2篇(1.94%)报道了双盲和单盲,14篇(1359%)进行了具体统计量计算,54篇(52.43%)提供了随访记录,7篇(6.80%)报道了阴性结果,16篇(15.53%)报道不良事件,仅有1篇(0.97%)进行样本含量计算与意向性分析(ITT),有2篇(1.94%)进行分层分析,属于多中心的仅有1篇(0.97%),均未进行伦理审批和知情同意。描述了中医证型的有3篇(2.91%)。结论:目前中药配合TACE辅助治疗原发性肝癌临床研究的方法学和报告质量尚低,且多数RCT可能存在选择性偏倚和测量性偏倚,期待更多高质量的随机双盲对照试验为临床应用提供可靠的依据。

    Release date:2016-09-08 10:14 Export PDF Favorites Scan
  • IN SITU MICROWAVE COAGULATION THERAPY FOR LIVER NEOPLASMS

    Objective To study the results of in situ microwave thermocoagulation therapy for liver neoplasms. Methods Thirty-one patients (male 28, female 3) with liver neoplasms underwent in situ microwave thermocoagulation therapy in recent 4 years were studied. The time of the therapy arranged from 2 to 6 minutes with the core temperature from 110℃ to 125℃. Twenty six of the thirty one (83.9%) were followed up. Results Ninty point three percent of these patients have a good result. The average survival time after the operation was 19.7 months. One-year and three-year survival rate were 77.4% and 38.7%, respectively. Conclusion The in situ microwave thermocoagulation therapy have the advantages of causing slight trauma, promoting repair, good tolerance and curative effectiveness. It’s a simple, safe and effective method with less adverse effect for treating the liver neoplasms, especially for unresectable neoplasms.

    Release date:2016-08-28 05:30 Export PDF Favorites Scan
  • Factors of Death after Hepatectomy in-Hospital and Prevention and Cure

    Release date:2016-09-08 11:07 Export PDF Favorites Scan
  • 老年肝脏未分化胚胎性肉瘤伴囊内出血1例报道

    Release date:2024-02-28 02:42 Export PDF Favorites Scan
  • Selection of Blood Occlusion in Operation of Hepatic Hemangioma

    目的探讨肝血管瘤切除术中血流阻断方法的选择。方法回顾性分析我院收治的19例肝血管瘤患者的手术方式。结果全组均行手术切除,术中出血50~1 500 ml(平均312 ml)。 术中根据血管瘤所在位置选择不同肝血流阻断方法,其中行半肝血流阻断4例,运用Glisson蒂横断式肝切除术或其分段原理阻断Glisson系统分支6例,间断阻断第一肝门7例,预置肝上、下下腔静脉和第一肝门阻断带并间断阻断第一肝门2例。 术后5例并发右侧胸腔积液,均经保守治疗后好转,手术并发症发生率为26.3%(5/19)。 术后住院7~41 d(平均16.9 d),均治愈出院。12例患者获随访,随访0.3~2年(平均1.1年),术前有症状的8例患者症状均消失,无复发,1例残留肝内血管瘤(直径lt;2 cm)。结论肝血管瘤患者肝切除术中的入肝血流阻断应强调个体化,根据肿瘤位置及大小选择不同的阻断方法,使患者术中出血少,术后恢复快。

    Release date:2016-09-08 10:46 Export PDF Favorites Scan
  • IMMUNE RESPONSES INDUCED BY HepG2 CELLS EXPRESSING B7-1 OR IL-12 MOLECULES

    Objective To investigate the effect of B7-1 and IL-12 gene expression on the immunogenicity of hepatocellular carcinoma (HCC) HepG2 cells. Methods Plasmids encoding B7-1 and IL-12 molecules were retrovirally introduced into human HCC cells,empty vector as control. PBLs were cocultured with HepG2/B7-1,HepG2/IL-12 and HepG2/neo cells. Three days later,PBLs were submitted to specific cytotoxicity test and nonspecific cytotoxicity test against K562 cells by MTT assay.Results HLA-Ⅰ molecules on PBLs were detected by FACS.HLA-Ⅰ molecules expressing on PBL cocultured with HepG2/B7-1,HepG2/IL-12 cells were enhanced by 16.95% and 14.71% than those of HepG2/neo group, respectively(P<0.05). Specific cytotoxicity against HepG2/B7-1 cells was 12.5% higher than that of against HepG2/neo cell,while no increase in that of against HepG2/IL-12 cells. Cytotoxicities against K562 cells in HepG2/B7-1,HepG2/IL-12 groups were 19.38% and 14.78% higher than those of HepG2/neo group, but no significant difference between the first two groups.Conclusion B7-1 and IL-12 gene transfer could remarkably promote immunogenicity of hepatocellular carcinoma cells and induce b specific and nonspecific immunity against hepatocellular carcinoma in vitro.

    Release date:2016-09-08 02:00 Export PDF Favorites Scan
  • REPEAT HEPATIC RESECTION FOR RECURRENT HEPATOCELLULAR CARCINOMA AFTER PRIMARY RESECTION

    This paper reports twelve patients underwent repeat hepatic resection because of the recurrence of hepatocellular carcinomas after primary resection. The indication of reoperation, selection of incision, difficults encountered in the operation and the treatment after operation are discussed. The authors believe that the second operation is technically more difficult than the first one, some troubles my be happened during the operation and put forward some ways to deal with this situations.

    Release date:2016-08-29 03:26 Export PDF Favorites Scan
  • mRNA EXPRESSION OF nm23-H1 GENE IN HUMAN LIVER TUMOR ASSAYED BY REVERSE TRANSCRIPTIONPOLYMERASE CHAIN REACTION

    To investigate the mRNA expression of nm23-H1 gene in human liver tumor. In tumor and corresponding nontumoral liver specimens from 20 patients, nm23-H1 mRNA were examined by reverse transcriptionpolymerase chain reaction (RT-PCR) method with specific primers. Results: The primers designed in this study could amplified nearly entire coding sequence of nm23-H1 gene. All the samples showed positive expression of nm23-H1 mRNA, indicating there was no expression loss or obvious alteration. Conclusions: The achievement of RT-PCR method lays foundation for quantitative gaugement of nm23-H1 mRNA in liver tumor.

    Release date:2016-08-29 09:20 Export PDF Favorites Scan
  • Totally Laparoscopic Associating Liver Tourniquet and Portal Ligation for Staged Hepatectomy Using The Anterior Approach Techniquefor Hepatocellular Carcinoma with Hepatitis B Cirrhosis

    ObjectiveTo investigate the application value of totally laparoscopic associating liver tourniquet and portal ligation for staged hepatectomy (ALTPS) using the anterior approach technique for hepatocellular carcinoma (HCC) with hepatitis B cirrhosis. MethodsIn September, 2014, a patient suffered cirrhotic hepatocellular carcinoma in the right liver scheduled for two-stage liver resection, in whom the future liver remnant (FLR) was considered too small (FLR/standard liver volume:29.1%, FLR/body wight:0.49%). In the first stage, using totally laparoscopic technique, a tourniquet was placed around the parenchymal transection line on the Cantlie's line via an anterior approach through retrohepatic tunnel for staged right hepatectomy, and the right portal vein was ligated. In the second stage, totally laparoscopic right hemihepatectomy was carried out on 10 days after the first-stage operation that achieved sufficient hypertrophy of the FLR. ResultsThe FLR on postoperative day 4 of the first stage increased from 301.48 to 496.45 mL (FLR/standard liver volume:47.9%, FLR/body wight:0.81%), with a 64.67% hypertrophy. And the FLR on postoperative day 8 of the first stage increased to 510.96 mL (FLR/standard liver volume:49.3%, FLR/body wight:0.84%), with a 69.48% hypertrophy. The remnant liver volume on postoperative day 5 of the second stage increased to 704.53 mL. The duration of the first stage was 180 min, intraoperative blood loss was 50 mL, and patient did not received a blood transfusion. The duration of the second stage was 220 min, intraoperative blood loss was 400 mL, and patient did not required a blood transfusion. No serious complications happened. The patient was discharged on 7 days after the second stage. ConclusionsAs a effective, safe, simple, and "non-touch" technique which provided a less aggressive modification of the ALPPS procedureto achieve oncological efficacy, the totally laparoscopic ALTPS using the anterior approach technique also could achieve sufficient hypertrophy of the FLR in several days. A proper expansion of the indications for the procedure is safe and feasible in HCC patients with cirrhosis.

    Release date: Export PDF Favorites Scan
3 pages Previous 1 2 3 Next

Format

Content